{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:30:23Z","timestamp":1784748623909,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K14669"],"award-info":[{"award-number":["23K14669"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This retrospective study aimed to assess the efficacy and safety of palliative radiotherapy for painful non-bone lesions in patients with advanced cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We enrolled patients with painful non-bone lesions who underwent conventional palliative radiotherapy between September 2018 and September 2022. The treatment targets included primary tumor lesions, lymph node metastases, non-bone hematogenous metastases, and other lesions. The primary endpoint was the overall pain response rate in evaluable patients, determined based on the International Consensus Pain Response Endpoint criteria. The secondary endpoints included overall survival, pain recurrence, and adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 420 screened patients, 142 received palliative radiotherapy for painful non-bone lesions, and 112 were evaluable. A pain response was achieved in 67 patients (60%) of the 112 evaluable patients within a median of 1.2\u00a0months. Among these patients, 25 exhibited complete response, 42 partial response, 18 indeterminate response, and 27 pain progression. The median survival time was 5.5\u00a0months, recorded at a median follow-up of 6.0\u00a0months, during which 67 patients died. Multivariate analysis identified poor performance status scores of 2\u20134, opioid use, and re-irradiation as independent factors associated with a reduced likelihood of achieving a pain response. Pain recurrence occurred in 18 patients over a median of 4.1\u00a0months. Seventeen patients had grade 1\u20132 adverse events, while none experienced grade 3 or higher toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Palliative radiotherapy can potentially be a safe and well-tolerated modality for managing painful non-bone lesions, with a low rate of adverse events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11604-024-01536-0","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T07:03:51Z","timestamp":1708585431000},"page":"656-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Palliative radiotherapy for painful non-bone lesions in patients with advanced cancer: a single center retrospective study"],"prefix":"10.1007","volume":"42","author":[{"given":"Yurika","family":"Shindo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8066-8753","authenticated-orcid":false,"given":"Yutaro","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Naganawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"1536_CR1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","volume":"18","author":"MHJ van den Beuken-van Everdingen","year":"2007","unstructured":"van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437\u201349.","journal-title":"Ann Oncol"},{"key":"1536_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MHJ van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51:1070-1090.e9.","journal-title":"J Pain Symptom Manag"},{"key":"1536_CR3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ijrobp.2023.01.050","volume":"116","author":"N Imano","year":"2023","unstructured":"Imano N, Saito T, Hoskin P, Nakamura N, Ito K, Yorozu A, et al. Pain response rates after conventional radiation therapy for bone metastases assessed using international consensus pain response endpoints: a systematic review and meta-analysis of initial radiation therapy and reirradiation. Int J Radiat Oncol Biol Phys. 2023;116:739\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1536_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","volume":"126","author":"SE Rich","year":"2018","unstructured":"Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126:547\u201357.","journal-title":"Radiother Oncol"},{"key":"1536_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13014-022-02128-w","volume":"17","author":"K Ito","year":"2022","unstructured":"Ito K, Saito T, Nakamura N, Imano N, Hoskin P. Stereotactic body radiotherapy versus conventional radiotherapy for painful bone metastases: a systematic review and meta-analysis of randomised controlled trials. Radiat Oncol. 2022;17:156.","journal-title":"Radiat Oncol"},{"key":"1536_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.prro.2018.11.006","volume":"9","author":"T Saito","year":"2019","unstructured":"Saito T, Toya R, Oya N. Pain response rates after conventional radiation therapy for bone metastases in prospective nonrandomized studies: a systematic review. Pract Radiat Oncol. 2019;9:81\u20138.","journal-title":"Pract Radiat Oncol"},{"key":"1536_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clon.2019.03.042","volume":"31","author":"T Saito","year":"2019","unstructured":"Saito T, Tomitaka E, Toya R, Oya N. Possible dose e response relationship in palliative radiotherapy for non-bone painful lesions. Clin Oncol. 2019;31:391\u20138.","journal-title":"Clin Oncol"},{"key":"1536_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13014-021-01900-8","volume":"16","author":"K Yamaguchi","year":"2021","unstructured":"Yamaguchi K, Saito T, Toya R, Tomitaka E, Matsuyama T, Fukugawa Y, et al. Palliative radiotherapy for painful lymph node metastases. Radiat Oncol. 2021;16:178.","journal-title":"Radiat Oncol"},{"key":"1536_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clon.2004.09.008","volume":"17","author":"SC Erridge","year":"2005","unstructured":"Erridge SC, Gaze MN, Price A, Kelly CG, Kerr GR, Cull A, et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol. 2005;17:61\u20137.","journal-title":"Clin Oncol"},{"key":"1536_CR10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0360-3016(02)02989-9","volume":"54","author":"A Bezjak","year":"2002","unstructured":"Bezjak A, Dixon P, Brundage M, Tu D, Palmer MJ, Blood P, et al. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002;54:719\u201328.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1536_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00066-017-1154-5","volume":"193","author":"M Rudzianskiene","year":"2017","unstructured":"Rudzianskiene M, Inciura A, Gerbutavicius R, Rudzianskas V, Macas A, Simoliuniene R, et al. Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma. Strahlenther Onkol. 2017;193:742\u20139.","journal-title":"Strahlenther Onkol"},{"key":"1536_CR12","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41598-020-58108-1","volume":"10","author":"CSY Yeung","year":"2020","unstructured":"Yeung CSY, Chiang CL, Wong NSM, Ha SK, Tsang KS, Ho CHM, et al. Palliative liver radiotherapy (RT) for symptomatic hepatocellular carcinoma (HCC). Sci Rep. 2020;10:1254.","journal-title":"Sci Rep"},{"key":"1536_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jjco\/hyac050","volume":"52","author":"K Ito","year":"2022","unstructured":"Ito K, Ogoshi Y, Shimizuguchi T. Palliative radiotherapy for multiple liver metastases: a retrospective analysis of 73 cases. Jpn J Clin Oncol. 2022;52:779\u201384.","journal-title":"Jpn J Clin Oncol"},{"key":"1536_CR14","first-page":"LBA492","volume":"41","author":"LA Dawson","year":"2023","unstructured":"Dawson LA, Fairchild AM, Dennis K, Mahmud A, Stuckless TL, Vincent F, et al. Canadian cancer trials group HE.1: a phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases. J Clin Orthod. 2023;41:LBA492.","journal-title":"J Clin Orthod"},{"key":"1536_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","volume":"94","author":"JT Farrar","year":"2001","unstructured":"Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149\u201358.","journal-title":"Pain"},{"key":"1536_CR16","unstructured":"NCCN guidelines available at http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp (Accessed on 7 May 2023). Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pain.pdf"},{"key":"1536_CR17","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.ijrobp.2011.02.008","volume":"82","author":"E Chow","year":"2012","unstructured":"Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82:1730\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1536_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","volume":"173","author":"J van der Velden","year":"2022","unstructured":"van der Velden J, Willmann J, Spa\u0142ek M, Oldenburger E, Brown S, Kazmierska J, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol. 2022;173:197\u2013206.","journal-title":"Radiother Oncol"},{"key":"1536_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2022.06.002","volume":"173","author":"E Oldenburger","year":"2022","unstructured":"Oldenburger E, Brown S, Willmann J, van der Velden JM, Spa\u0142ek M, van der Linden YM, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiother Oncol. 2022;173:240\u201353.","journal-title":"Radiother Oncol"},{"key":"1536_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7:4\u201312.","journal-title":"Pract Radiat Oncol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-024-01536-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01536-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T10:00:19Z","timestamp":1717063219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-024-01536-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s11604-024-01536-0","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YK has a speaker\u2019s bureau for Hitachi Co. and has received research funding from the JSPS (Grant Number 23K14669). TK has speaker bureaus at Hitachi Co., Bristol Myers Squibb, Accuray Co., Elekta Co., Ono Pharmaceutical Co., AstraZeneca Co., Taiho Pharmaceutical Co., Canon Co., and Janssen Pharmaceutical Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board of our institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}